Spondyloarthropathies News

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

The effectiveness of TNF inhibitors for axial spondyloarthritis varies significantly between men and women based on BASDAI score, but not ASDAS, according to data published in Arthritis Research & Therapy.

DESTIN, Fla. — New data on discontinuation or dose reduction of biologic therapies has led to a shifting landscape in axial spondyloarthritis management, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Ultrasound can differentiate spondyloarthritis-related enthesitis from other entheseal pathologies such as mechanical enthesitis, according to data published in Annals of the Rheumatic Diseases.

Among patients with rheumatic diseases, the risk for cardiovascular comorbidity is highest during the period immediately before or after initial diagnosis, according to data published in Seminars in Arthritis and Rheumatism.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

Pregnant patients with lupus or antiphospholipid syndrome have a higher risk for preterm birth, although immune-mediated inflammatory diseases in general are “only weakly associated” with adverse pregnancy outcomes, according to data.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.